Business Context and Reporting Period
This Form 8-K was filed by BioRestorative Therapies, Inc. on April 2, 2012, reporting a corporate event that occurred on the same date. The Company is incorporated in Nevada and operates through a wholly-owned subsidiary, Stem Cell Cayman, Ltd.
Key Financial Metrics and Obligations
The filing details a new direct financial obligation created on April 2, 2012:
- Loan Amount: $1,500,000 borrowed by Stem Cell Cayman, Ltd. from Westbury (Bermuda) Ltd., a principal shareholder.
- Interest Rate: 15% per annum, payable monthly.
- Maturity: Principal due one year from issuance, subject to acceleration under certain circumstances.
- Equity Consideration: Issuance of a five-year warrant for 20,000,000 shares of common stock at an exercise price of $0.03 per share.
The filing text does not provide clear values for revenue, profit, cash flow, margins, or existing liquidity positions.
Material Changes
The primary material change is the incurrence of $1.5 million in debt and the issuance of significant equity warrants. This transaction increases the Company's leverage and potential future dilution. No prior comparable period data is provided in this specific filing to quantify changes in financial performance.
Outlook, Risks, and Contingencies
The filing does not contain management commentary, forward-looking guidance, or a discussion of general risks. The specific contingency noted is the acceleration clause attached to the promissory note, which allows the lender to demand immediate repayment of the principal under certain circumstances.
Investor Verification Checklist
- Verify the current cash position of the Company to assess the ability to service the 15% monthly interest payments.
- Confirm the total outstanding share count to evaluate the dilution impact of the 20,000,000 warrant shares.
- Review the specific "certain circumstances" defined in the promissory note that trigger acceleration of the debt.
- Assess the relationship and voting power of Westbury (Bermuda) Ltd. as a principal shareholder.